Literature DB >> 27699149

Expression of P40 and P63 in lung cancers using fine needle aspiration cases. Understanding clinical pitfalls and limitations.

Mohammed T Lilo1, Derek Allison1, Yuting Wang2, MingHui Ao1, Edward Gabrielson1, Susan Geddes1, Hui Zhang1, Frederic Askin1, Qing Kay Li1.   

Abstract

BACKGROUND: Fine-needle aspiration (FNA) biopsy of lung lesions is a highly accurate method for diagnosing and staging of lung cancers, particularly in patients with advanced cancer. Although, the majority of FNA cases of non-small cell lung carcinoma (NSCLC) can be subclassified by hematoxylin and eosin (H&E) sections, immunohistochemical (IHC) markers are usually necessary for difficult cases. Our previous study has shown that both P40 and P63 demonstrate differential sensitivity and specificity in the subclassification of squamous cell carcinoma (SqCC) using tumor tissue microarrays (TMA). In the present study, we further evaluated the utility of P40 and P63 and the potential pitfalls and limitations associated with the usefulness of these stains in FNA cases.
METHODS: By a computer search of pathology archives, 144 FNA biopsies with diagnoses of lung cancers and P40/P63 stains were identified, including 50 adenocarcinomas (ADCs), 56 SqCCs, 8 small cell lung carcinomas (SCLCs), and 12 cases of poorly differentiated carcinoma (PD CA). Ten benign FNA lung lesions and 8 other malignant neoplasms were also included as controls. Nuclear staining patterns of P40 and P63 were scored semi-quantitatively as 0 (negative), 1 (<10%, weak and focal), or 2 (>10%, strong and diffuse).
RESULTS: In lung SqCCs, P40 and P63 were positive in 77.3% and 89.5% cases, respectively. In ADCs, P40 was weakly and focally positive in 6.1% cases, and P63 was variably positive in 62.8% cases. In SCLCs, P40 and P63 were focally positive in 12.5% and 50% cases. In PD CAs, no P40 or P63 immunoreactivity was detected. In the group of other neoplasms (n=8) both P40 and P63 were positive in the case of metastatic non-seminomatous germ cell tumor (NSGCT) (n=1), and P63 was positive in the case of metastatic Merkel cell carcinoma (n=1). The sensitivity and specificity of P40 and P63 were 76.9%/93.3%, and 90.2%/50.7% in the lung SqCC.
CONCLUSIONS: P63 has a better sensitivity, and P40 has a better specificity for SqCC. A positive staining pattern with both markers was also found in certain non-SqCC cases. Recognizing limitations of these markers are particularly important in FNA cases.

Entities:  

Keywords:  P40 and P63; fine needle aspiration of lung cancers; immunohistochemical markers; non-small cell lung carcinoma (NSCLC)

Year:  2016        PMID: 27699149      PMCID: PMC5044754          DOI: 10.1016/j.jasc.2015.07.002

Source DB:  PubMed          Journal:  J Am Soc Cytopathol        ISSN: 2213-2953


  36 in total

Review 1.  Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

Authors:  Helena Linardou; Issa J Dahabreh; Dimitra Kanaloupiti; Fotios Siannis; Dimitrios Bafaloukos; Paris Kosmidis; Christos A Papadimitriou; Samuel Murray
Journal:  Lancet Oncol       Date:  2008-09-17       Impact factor: 41.316

2.  Erlotinib in lung cancer - molecular and clinical predictors of outcome.

Authors:  Ming-Sound Tsao; Akira Sakurada; Jean-Claude Cutz; Chang-Qi Zhu; Suzanne Kamel-Reid; Jeremy Squire; Ian Lorimer; Tong Zhang; Ni Liu; Manijeh Daneshmand; Paula Marrano; Gilda da Cunha Santos; Alain Lagarde; Frank Richardson; Lesley Seymour; Marlo Whitehead; Keyue Ding; Joseph Pater; Frances A Shepherd
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

3.  High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.

Authors:  Nobukazu Fujimoto; Marie Wislez; Jie Zhang; Kentaro Iwanaga; Jennifer Dackor; Amy E Hanna; Shailaja Kalyankrishna; Dianna D Cody; Roger E Price; Mitsuo Sato; Jerry W Shay; John D Minna; Michael Peyton; Ximing Tang; Erminia Massarelli; Roy Herbst; David W Threadgill; Ignacio I Wistuba; Jonathan M Kurie
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

Review 4.  Novel therapeutic targets in non-small cell lung cancer.

Authors:  Filip Janku; Ignacio Garrido-Laguna; Lubos B Petruzelka; David J Stewart; Razelle Kurzrock
Journal:  J Thorac Oncol       Date:  2011-09       Impact factor: 15.609

5.  KEAP1 gene mutations and NRF2 activation are common in pulmonary papillary adenocarcinoma.

Authors:  Qing Kay Li; Anju Singh; Shyam Biswal; Frederic Askin; Edward Gabrielson
Journal:  J Hum Genet       Date:  2011-01-20       Impact factor: 3.172

6.  Cytomorphology of sebaceous carcinoma with analysis of p40 antibody expression.

Authors:  Deepali Jain; Sandeep R Mathur; Mehar C Sharma; Venkateswaran K Iyer
Journal:  Diagn Cytopathol       Date:  2015-01-22       Impact factor: 1.582

7.  ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent.

Authors:  T Mitsudomi; S M Steinberg; H K Oie; J L Mulshine; R Phelps; J Viallet; H Pass; J D Minna; A F Gazdar
Journal:  Cancer Res       Date:  1991-09-15       Impact factor: 12.701

Review 8.  Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.

Authors:  Tetsuya Mitsudomi; Yasushi Yatabe
Journal:  Cancer Sci       Date:  2007-09-20       Impact factor: 6.716

9.  p40 (ΔNp63) is more specific than p63 and cytokeratin 5 in identifying squamous cell carcinoma of bronchopulmonary origin: a review and comparative analysis.

Authors:  Adam P Vogt; Cynthia Cohen; Momin T Siddiqui
Journal:  Diagn Cytopathol       Date:  2013-10-25       Impact factor: 1.582

10.  The significance of p40 expression in sclerosing hemangioma of lung.

Authors:  Jian Wu; Chang Zhang; Haiguo Qiao
Journal:  Sci Rep       Date:  2014-08-18       Impact factor: 4.379

View more
  7 in total

Review 1.  Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.

Authors:  Lais Osmani; Frederic Askin; Edward Gabrielson; Qing Kay Li
Journal:  Semin Cancer Biol       Date:  2017-11-26       Impact factor: 15.707

2.  The value of AGR2 and KRT5 as an immunomarker combination in distinguishing lung squamous cell carcinoma from adenocarcinoma.

Authors:  Bo Pan; Zi-Xin Wei; Ju-Xuan Zhang; Xin Li; Qing-Wei Meng; Ying-Yue Cao; Li-Shuang Qi; Yan Yu
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

3.  Greater specificity of p40 compared with p63 in distinguishing squamous cell carcinoma from adenocarcinoma in effusion cellblocks.

Authors:  Nah Ihm Kim; Ji Shin Lee
Journal:  Cytojournal       Date:  2020-06-08       Impact factor: 2.091

4.  Useful Application of Immunostaining to Malignant Pleural Effusion among Lao People in Vientiane Capital, Lao PDR

Authors:  Soulideth Vilayvong; Kiyomi Hando; Masaki Sekine; Thitsamay Luangxay; Phetsamone Arounlangsy; Pheangvilay Xaysomphet; Phetlammone Xayaphet; Hatthakone Thavisouk; Yurie Soejima; Masanobu Kitagawa; Motoji Sawabe
Journal:  Asian Pac J Cancer Prev       Date:  2019-01-25

5.  P40 expression in small cell lung cancer: The presence of p40-positive cells does not always indicate squamous differentiation.

Authors:  Naoki Nakajima; Akihiko Yoshizawa; Koki Moriyoshi; Makoto Sonobe; Toshi Menju; Shinji Sumiyoshi; Hiroshi Date; Hironori Haga
Journal:  Thorac Cancer       Date:  2019-04-07       Impact factor: 3.500

6.  Glypican-1 is a novel immunohistochemical marker to differentiate poorly differentiated squamous cell carcinoma from solid predominant adenocarcinoma of the lung.

Authors:  Yuichiro Kai; Vishwa Jeet Amatya; Kei Kushitani; Takahiro Kambara; Rui Suzuki; Yutaro Fujii; Yasuhiro Tsutani; Yoshihiro Miyata; Morihito Okada; Yukio Takeshima
Journal:  Transl Lung Cancer Res       Date:  2021-02

7.  Primary Intrahepatic Squamous Cell Carcinoma with Histological Collision of Adenocarcinoma and Squamous Cell Carcinoma: A Case Report.

Authors:  Kohei Tamaoka; Masahiro Tanemura; Kenta Furukawa; Manabu Mikamori; Takuro Saito; Masahisa Ohtsuka; Yozo Suzuki; Mitsuyoshi Tei; Kentaro Kishi; Hironao Yasuoka; Masahiko Tsujimoto; Hiroki Akamatsu
Journal:  Am J Case Rep       Date:  2018-10-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.